{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29
  ],
  "modelUsed": "gemini-3-flash-preview",
  "studyDesignStructure": {
    "studyArms": [
      {
        "id": "arm_1",
        "name": "Brolucizumab 6 mg",
        "type": {
          "code": "Experimental Arm",
          "codeSystem": "USDM",
          "decode": "Experimental Arm"
        },
        "instanceType": "StudyArm",
        "description": "Intravitreal injection of 6 mg brolucizumab. Loading phase: 3 injections every 6 weeks (q6w) at Baseline, Week 6, and Week 12. Maintenance phase: q12w injections through Week 90, with potential extension up to q24w after Week 48."
      },
      {
        "id": "arm_2",
        "name": "Panretinal Photocoagulation (PRP)",
        "type": {
          "code": "Active Comparator Arm",
          "codeSystem": "USDM",
          "decode": "Active Comparator Arm"
        },
        "instanceType": "StudyArm",
        "description": "Initial laser treatment in 1-4 sessions up to Week 12, followed by additional PRP treatment as needed up to Week 90."
      }
    ],
    "studyCells": [
      {
        "id": "cell_1",
        "armId": "arm_1",
        "epochId": "epoch_1",
        "elementIds": [
          "elem_1"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_2",
        "armId": "arm_1",
        "epochId": "epoch_2",
        "elementIds": [
          "elem_2"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_3",
        "armId": "arm_1",
        "epochId": "epoch_3",
        "elementIds": [
          "elem_3"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_4",
        "armId": "arm_2",
        "epochId": "epoch_1",
        "elementIds": [
          "elem_4"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_5",
        "armId": "arm_2",
        "epochId": "epoch_2",
        "elementIds": [
          "elem_5"
        ],
        "instanceType": "StudyCell"
      },
      {
        "id": "cell_6",
        "armId": "arm_2",
        "epochId": "epoch_3",
        "elementIds": [
          "elem_6"
        ],
        "instanceType": "StudyCell"
      }
    ],
    "studyCohorts": [],
    "studyElements": [
      {
        "id": "elem_1",
        "name": "Brolucizumab 6 mg - Screening period",
        "instanceType": "StudyElement",
        "description": "Treatment period for Brolucizumab 6 mg during Screening period"
      },
      {
        "id": "elem_2",
        "name": "Brolucizumab 6 mg - Single-masked treatment period",
        "instanceType": "StudyElement",
        "description": "Treatment period for Brolucizumab 6 mg during Single-masked treatment period"
      },
      {
        "id": "elem_3",
        "name": "Brolucizumab 6 mg - Post-treatment follow-up period",
        "instanceType": "StudyElement",
        "description": "Treatment period for Brolucizumab 6 mg during Post-treatment follow-up period"
      },
      {
        "id": "elem_4",
        "name": "Panretinal Photocoagulation (PRP) - Screening period",
        "instanceType": "StudyElement",
        "description": "Treatment period for Panretinal Photocoagulation (PRP) during Screening period"
      },
      {
        "id": "elem_5",
        "name": "Panretinal Photocoagulation (PRP) - Single-masked treatment period",
        "instanceType": "StudyElement",
        "description": "Treatment period for Panretinal Photocoagulation (PRP) during Single-masked treatment period"
      },
      {
        "id": "elem_6",
        "name": "Panretinal Photocoagulation (PRP) - Post-treatment follow-up period",
        "instanceType": "StudyElement",
        "description": "Treatment period for Panretinal Photocoagulation (PRP) during Post-treatment follow-up period"
      }
    ],
    "summary": {
      "armCount": 2,
      "cellCount": 6,
      "cohortCount": 0,
      "elementCount": 6
    },
    "studyDesign": {
      "id": "sd_1",
      "name": "Study Design",
      "instanceType": "InterventionalStudyDesign",
      "trialIntentTypes": [
        {
          "code": "Treatment",
          "codeSystem": "USDM",
          "decode": "Treatment"
        }
      ],
      "trialType": {
        "code": "Interventional",
        "codeSystem": "USDM",
        "decode": "Interventional"
      },
      "blindingSchema": {
        "code": "Single Blind",
        "codeSystem": "USDM",
        "decode": "Single Blind"
      },
      "maskedRoles": [
        "Subject",
        "Outcome Assessor",
        "Data Analyst"
      ],
      "randomizationType": {
        "code": "Randomized",
        "codeSystem": "USDM",
        "decode": "Randomized"
      },
      "allocationRatio": {
        "ratio": "1:1"
      },
      "stratificationFactors": [
        "Baseline DR Severity category",
        "Age category",
        "Region"
      ],
      "controlType": {
        "code": "Active Control",
        "codeSystem": "USDM",
        "decode": "Active Control"
      },
      "armIds": [
        "arm_1",
        "arm_2"
      ],
      "therapeuticAreas": [
        "Ophthalmology"
      ]
    }
  },
  "rawResponse": {
    "studyDesign": {
      "type": "Interventional",
      "trialIntentTypes": [
        "Treatment"
      ],
      "blinding": {
        "schema": "Single Blind",
        "maskedRoles": [
          "Subject",
          "Outcome Assessor",
          "Data Analyst"
        ]
      },
      "randomization": {
        "type": "Randomized",
        "allocationRatio": "1:1",
        "stratificationFactors": [
          "Baseline DR Severity category",
          "Age category",
          "Region"
        ]
      },
      "controlType": "Active Control",
      "therapeuticAreas": [
        "Ophthalmology"
      ]
    },
    "arms": [
      {
        "name": "Brolucizumab 6 mg",
        "type": "Experimental Arm",
        "description": "Intravitreal injection of 6 mg brolucizumab. Loading phase: 3 injections every 6 weeks (q6w) at Baseline, Week 6, and Week 12. Maintenance phase: q12w injections through Week 90, with potential extension up to q24w after Week 48.",
        "isTitration": false
      },
      {
        "name": "Panretinal Photocoagulation (PRP)",
        "type": "Active Comparator",
        "description": "Initial laser treatment in 1-4 sessions up to Week 12, followed by additional PRP treatment as needed up to Week 90.",
        "isTitration": false
      }
    ],
    "cohorts": [],
    "epochs": [
      {
        "name": "Screening period",
        "description": "Day -21 to Day -1; assessment of eligibility and PDR status."
      },
      {
        "name": "Single-masked treatment period",
        "description": "Day 1 to Week 90; randomized treatment administration."
      },
      {
        "name": "Post-treatment follow-up period",
        "description": "Week 90 to Week 96; end-of-study assessments 6 weeks after last possible treatment."
      }
    ]
  }
}